We are a clinical-stage biopharmaceutical company seeking to bring life into balance for patients suffering with Graves’ disease (GD) and thyroid eye disease (TED). We are led by a team with extensive experience in scientific innovation, clinical development and company building, and have a deep history of developing innovative treatments with the potential to make a significant impact on patients’ lives.
Current treatments for GD and TED are very limited, and the ones available are associated with serious side effects that may restrict benefits or have long-term health impacts. Yarrow is developing YB-101, a potentially first-in-class inhibitor of the thyroid stimulating hormone receptor (TSHR), which directly disrupts the central autoimmune mechanism responsible for GD and TED. By directly binding to TSHR and protecting this receptor from autoantibody attack, YB-101 offers the potential to address both thyroidal and extra-thyroidal manifestations of these diseases without the risk of serious toxicities or immunosuppression, thereby delivering rapid, predictable control of these devastating autoimmune conditions.
